iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Biocon stock surges 3% after Q3 PAT rises by 11% yoy to Rs187cr as robust growth seen across segments

21 Jan 2022 , 12:08 PM

Biocon Limited

Bangalore-based biopharmaceutical company, Biocon posted a consolidated net profit of Rs187cr in the quarter ending December 2021 (Q3FY22) rising by 11% from Rs169cr in the corresponding period of the previous year. These profits are for shareholders of the company.

The company’s revenue from operations stood at Rs2,174cr in Q3FY22 increasing by a whopping 17% from Rs1,857cr of the December quarter last year. In segment-wise performance, the Generics business recorded growth of 7% yoy, while the Biosimilars business rose by 28% yoy and Novel Biologics increases by 100% yoy. Further, the Research services and Inter-segment growth stood at 10% yoy and 13% yoy.

Kiran Mazumdar-Shaw, Executive Chairperson, Biocon, said, “Biocon’s consolidated Q3FY22 revenues grew by 18% YoY to Rs 2,223 Crore, driven by a strong performance across all business segments. Biosimilars grew by 28% to Rs 981 Crore, Research Services was up 10% at Rs 641 Crore and Generics delivered a 7% growth at Rs 607 Crore.”

“EBITDA at Rs 537 Crore grew by 25%, which was impacted by mark- to- market loss attributed to Biocon Biologics’ equity investment in Adagio. Core EBITDA stood at Rs 715 Crore with a healthy margin of 33%. PBT for the quarter stood at Rs 269 Crore. Adjusted for Adagio related loss, PBT was higher at Rs 346 Crore, indicating a healthy operating profitability,” Mazumdar-Shaw added.

On Biocon Biologics, she said that it “achieved a key milestone with the commercialization of the world’s first interchangeable biosimilar, our Insulin Glargine, in the U.S.. Approvals for several of our generics and biosimilars in global markets, and renewal of key long-term research service agreements at Syngene, position us for a strong close to this fiscal.”

At around 12.05 pm, Biocon was trading at Rs373.95 per piece up by 2.8% on Sensex. The stock was near the day’s high of Rs374.50 per piece. 

Related Tags

  • Biocon
  • Biocon earnings
  • Biocon Q3 financial performance
  • Biocon Q3 highlights
  • Biocon Q3 results
  • Biocon Q3 review
  • Biocon Q3FY22
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.